Everest Re Group Ltd Valuation – Initial Coverage $RE
Company Profile (excerpt from Reuters): Everest Re Group, Ltd., incorporated on August 26, 1999, through its subsidiaries, is engaged in the underwriting of reinsurance and insurance in the United States, Bermuda and international markets. The Company operates in segments: U.S. Reinsurance, International, Bermuda and Insurance segment. The Company underwrites reinsurance both through brokers and directly with ceding companies. The Company underwrites insurance principally through general agent relationships, brokers and surplus lines brokers. The Company offers treaty and facultative reinsurance, and admitted and non-admitted insurance. Its products include the range of property and casualty reinsurance, and insurance coverage’s, including marine, aviation, surety, errors and omissions liability (E&O), directors’ and officers’ liability (D&O), medical malpractice, other specialty lines, accident and health (A&H) and workers’ compensation. The Company’s subsidiaries include Everest Reinsurance (Bermuda), Ltd. (Bermuda Re), Everest International Reinsurance, Ltd., Everest Reinsurance Company (Ireland) Limited (Ireland Re), Everest Reinsurance Company (Everest Re), Everest Insurance Company of Canada, Everest National Insurance Company, Everest Indemnity Insurance Company and Everest Security Insurance Company.
Downloadable PDF version of this valuation:
ModernGraham Valuation of RE – April 2018
Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?
What kind of Intelligent Investor are you?
| Defensive Investor; must pass all 6 of the following tests. | ||||
| 1. Adequate Size of the Enterprise | Market Cap > $2Bil | $10,596,480,007 | Pass | |
| 2. Earnings Stability | Positive EPS for 10 years prior | Fail | ||
| 3. Dividend Record | Dividend Payments for 10 years prior | Pass | ||
| 4. Earnings Growth | Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end | 146.95% | Pass | |
| 5. Moderate PEmg Ratio | PEmg < 20 | 13.37 | Pass | |
| 6. Moderate Price to Assets | PB Ratio < 2.5 OR PB*PEmg < 50 | 1.25 | Pass | |
| Enterprising Investor; must pass all 3 of the following tests, or be suitable for the Defensive Investor. | ||||
| 1. Earnings Stability | Positive EPS for 5 years prior | Pass | ||
| 2. Dividend Record | Currently Pays Dividend | Pass | ||
| 3. Earnings Growth | EPSmg greater than 5 years ago | Pass | ||
Stage 2: Determination of Intrinsic Value
| EPSmg | $19.22 |
| MG Growth Estimate | 0.10% |
| MG Value | $167.30 |
| Opinion | Overvalued |
| MG Grade | B- |
| MG Value based on 3% Growth | $278.73 |
| MG Value based on 0% Growth | $163.39 |
| Market Implied Growth Rate | 2.44% |
| Current Price | $257.04 |
| % of Intrinsic Value | 153.64% |
Everest Re Group Ltd is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years. The Enterprising Investor has no initial concerns. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.
As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $19.09 in 2014 to an estimated $19.22 for 2018. This level of demonstrated earnings growth does not support the market’s implied estimate of 2.44% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value below the price.
At the time of valuation, further research into Everest Re Group Ltd revealed the company was trading below its Graham Number of $306.32. The company pays a dividend of $5.05 per share, for a yield of 2% Its PEmg (price over earnings per share – ModernGraham) was 13.37, which was below the industry average of 22.6, which by some methods of valuation makes it one of the most undervalued stocks in its industry.
Everest Re Group Ltd performs fairly well in the ModernGraham grading system, scoring a B-.
Stage 3: Information for Further Research
| Graham Number | $306.32 |
| PEmg | 13.37 |
| PB Ratio | 1.25 |
| Dividend Yield | 1.96% |
| TTM Dividend | $5.05 |
| Number of Consecutive Years of Dividend Growth | 5 |
Useful Links:
| ModernGraham tagged articles | Morningstar |
| Google Finance | MSN Money |
| Yahoo Finance | Seeking Alpha |
| GuruFocus | SEC Filings |
Most Recent Balance Sheet Figures
| Balance Sheet Information | 12/1/2017 |
| Long-Term Debt & Capital Lease Obligation | $633,395,000 |
| Total Assets | $23,591,792,000 |
| Intangible Assets | $0 |
| Total Liabilities | $15,222,560,000 |
| Shares Outstanding (Diluted Average) | 40,816,000 |
Earnings Per Share History
| EPS History | |
| Next Fiscal Year Estimate | $20.35 |
| Dec2017 | $11.36 |
| Dec2016 | $23.68 |
| Dec2015 | $22.10 |
| Dec2014 | $25.91 |
| Dec2013 | $25.44 |
| Dec2012 | $15.79 |
| Dec2011 | -$1.49 |
| Dec2010 | $10.70 |
| Dec2009 | $13.22 |
| Dec2008 | -$0.30 |
| Dec2007 | $13.19 |
| Dec2006 | $12.87 |
| Dec2005 | -$3.79 |
| Dec2004 | $8.71 |
| Dec2003 | $7.74 |
| Dec2002 | $4.52 |
| Dec2001 | $2.10 |
| Dec2000 | $4.02 |
| Dec1999 | $3.25 |
| Dec1998 | $3.26 |
Earnings Per Share – ModernGraham History
| EPSmg History | |
| Next Fiscal Year Estimate | $19.22 |
| Dec2017 | $19.67 |
| Dec2016 | $23.41 |
| Dec2015 | $21.37 |
| Dec2014 | $19.09 |
| Dec2013 | $14.70 |
| Dec2012 | $8.75 |
| Dec2011 | $5.84 |
| Dec2010 | $9.65 |
| Dec2009 | $8.43 |
| Dec2008 | $6.07 |
| Dec2007 | $8.75 |
| Dec2006 | $6.35 |
| Dec2005 | $3.35 |
| Dec2004 | $6.42 |
| Dec2003 | $4.96 |
| Dec2002 | $3.52 |
Recommended Reading:
Other ModernGraham posts about the company
None. This is the first time ModernGraham has covered the company.
Other ModernGraham posts about related companies
Disclaimer:
The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.
